KDventures AB
2I9
Company Profile
Business description
KDventures AB is a Nordic investment company specialized in life sciences. The company identifies and invests in pharmaceutical projects and medical technology products originating from research institutions in the Nordic region. Through a diversified portfolio across various stages of development, professional due diligence, and active board engagement, the company creates value from early research to commercialization. The company offers investors exposure to both listed and private life science projects with value growth potential.
Contact
Nanna Svartz vag 6A
Solna171 65
SWET: +46 852486070
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
Eli Lilly receives FDA approval to add another oral GLP-1 to market
Wide moat Eli Lilly receives FDA approval for obesity pill.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Which of the 3 giant AI IPOs should you buy?
OpenAI, Anthropic, and Databricks are expected to go public this year at massive valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,810.60 | 89.10 | -1.00% |
| CAC 40 | 7,981.27 | 164.33 | 2.10% |
| DAX 40 | 23,298.89 | 618.85 | 2.73% |
| Dow JONES (US) | 46,565.74 | 224.23 | 0.48% |
| FTSE 100 | 10,364.79 | 188.34 | 1.85% |
| HKSE | 25,024.48 | 269.55 | -1.07% |
| NASDAQ | 21,840.95 | 250.32 | 1.16% |
| Nikkei 225 | 52,780.13 | 959.55 | -1.79% |
| NZX 50 Index | 12,865.18 | 39.31 | 0.31% |
| S&P 500 | 6,575.32 | 46.80 | 0.72% |
| S&P/ASX 200 | 8,612.20 | 72.80 | -0.84% |
| SSE Composite Index | 3,933.16 | 15.39 | -0.39% |